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Abstract 
The classical pathway of complement system, activated by immune complexes, involves 
binding of globular heads of C1q to the Fc regions of aggregated IgG or IgM. At the C-
terminal region of C1q, is globular head region (gC1q) where each globular head is 
composed of one A (ghA), one B (ghB) and one C (ghC) chain. In order to understand 
modularity of gC1q region of mouse C1q and to generate useful reagents for in vivo studies, 
we have expressed these recombinant individual heads of mouse C1q in Escherichia coli as 
soluble proteins linked to maltose-binding protein (MBP). This included RNA extraction and 
cDNA synthesis from mouse spleen, using appropriate primers, full-length mouse C1q A, B 
and C chains were amplified first. Following this, using the appropriate full length C1q 
chains, globular heads of mouse C1q A, B and C chains were amplified (mghA, mghB and 
mghC respectively). We have examined their interaction with heat-aggregated mouse IgG. 
These fusion proteins (MBP-ghA, -ghB, and -ghC) were found to bind differentially to mouse 
IgG.  ghA and ghB were found to bind highest with IgG. IgG subtypes were purified and their 
interaction with native human C1q was also studied. Dose-dependent binding was observed. 
Interaction of recombinant globular heads of C1q with mouse IgM was also examined. ghC 
was found to bind highest with IgM although ghB and ghA also showed binding to IgM. The 
ability of these recombinant heads to inhibit complement-mediated lysis was also 
examined. Both MBP-ghA and MBP-ghB also inhibited C1q-dependent hemolysis of IgG 
sensitized sheep erythrocytes. Interaction and binding of these globular heads with 
recombinant prion peptide was also studied. The individual globular heads of mouse C1q 
were also found to bind to recombinant mouse PrP peptide which will aid in better 
understanding of pathogenesis of prion disease. Further studies involved interaction of 
recombinant mouse globular heads of C1q (mghA, mghB and mghC) with pentraxin PTX-3. 
mghB and mghC showed highest binding (mghB>mghC) to PTX3 as compared to mghA. The 
study of recombinant gC1q region heads will help in understanding the effects of PTX3 
activation on the complement system. Collaborative studies examined the most variable 
residues in mouse gC1q region as well as alignment of mouse gC1q region with human gC1q 
region. The expression and functional characterisation of individual mouse gC1q domains 
has allowed to examine specificity and selectivity of individual globular heads of mouse C1q 
to known ligands. Production of mouse gC1q domains will be helpful in antibody mapping of 
anti-C1q autoantibodies recognising gC1q region. 
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1. Introduction 
1.1 Innate immunity and the complement system 
Innate immunity is the first line of defence against the invading pathogens and usually offers 
resistance within the first few hours to days (0-96 hours) of an infection (Murphy, 2012). It 
however does not possess the ability of specific immunity via recognition of pathogens viz. 
maintained by the adaptive immune system. Some of the components of first line of 
defence include epithelium (skin, gut, lungs) that acts as a physical barrier and also produce 
several kinds of antimicrobial enzymes and peptides namely lysozyme, defensins, mucin, 
lectin (Murphy, 2012). Once these are breached, next the pathogens come into contact with 
the complement system. Other components of innate immunity include the pattern-
recognition receptors (PRR). These recognise not only exogenous pathogen-associated 
molecular pattern (PAMP) but also endogenous modified molecules called damage-
associated molecular pattern (DAMP). The innate immune system launches inflammatory 
and regulatory responses with help of receptors, cells like phagocytes (macrophages) and 
mast cells, through different pathways, complement system and production of cytokines 
and chemokines to counteract infection, injury and maintenance of tissue homeostasis.  
The complement system 
The complement system comprises of more than 30 proteins in the serum as well as 
membrane-bound receptors and regulators. The complement system consists of 3 different 
initiating or activation pathways culminating into a final common lytic pathway, leading to 
the formation of membrane attack complex (MAC). MAC are pores that penetrate cell 
membrane (lipid bilayers) of pathogens or abnormal cells, thereby causing their lysis.  
The three initiating pathways are called (i) classical pathway which is mostly antibody 
mediated (C1q being the first subcomponent) and is activated by C1 complex (C1q-C1r-C1s); 
(ii) alternative pathway (AP) which is activated spontaneously involving low-level hydrolysis 
of C3 to C3 (H20); and (iii) lectin pathway where activation occurs through binding of a 
carbohydrate pattern present on microorganisms called mannan, with mannan-binding 
lectin (MBL) and Ficolins (ficolin-1, -2 and -3). They circulate in the serum in combination 
with zymogen serine proteases called MBL-associated serine proteases (MASPs) (Kishore 
and Reid, 2000; Shastri et al., 2013). 
All the 3 pathways ultimately converge to lead to formation of C3 convertase. C3 
convertases then cleaves C3 into C3a and C3b. This C3b binds to C3 convertase and leads to 
the formation of C5 convertase. This C5 convertase cleaves C5 into C5a and C5b. C3a and 
C5a are called anaphylatoxins and are chemoattractants. The C5b formed associates with 
C6, C7, C8, and C9 to form MAC (Shastri et al., 2013). The functions of the complement 
system include opsonisation of pathogens, direct lysis of foreign cells, chemotaxis and 
activation of leukocytes, and clearance of apoptotic cells. The complement system is kept in 
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check by regulators in order to prevent overactivation leading to damage to tissues and 
autoimmune diseases. The regulators can be grouped into fluid-phase: factor H (fH) and 
properdin for alternative pathway, C1 inhibitor and C4b-binding protein (C4BP) for classical 
and MBL pathway; host cell membrane-bound: CR1, CR2, CD55, CD46, CD59; cell surface-
attached complement regulators: fH, factor H-like protein 1 (FHL-1), C4BP and clusterin 
(Shastri et al., 2013). For certain ligands, factor H can also regulate C1q-mediated classical 
pathway (Kishore and Sim, 2012, Tan et al., 2010; Tan et al., 2011; Kang et al., 2012). 
 
Figure 1. The complement system consists of three activating pathways namely classical, alternative and lectin 
pathways. The classical pathway is activated by antigen-antibody complexes binding to C1q, while the lectin 
pathway is activated by binding of mannose (present on microbes) to membrane associated serine proteases 
(MASPs). This leads to formation of a common C3 convertase (C4b2a). The alternative pathway is 
spontaneously activated by low-level hydrolysis of C3 to C3(H2O), leading to formation of C3 convertase 
(C3bBb). The C3 convertases leads to formation of C3b and C3a. Then, C3b is involved in the formation of C5 
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converatses which leads to formation of C5b and C5a. C3a and C5a are anaphylotoxins. C5b combines with C6, 
C7,C8 and C9 to form membrane attack complex.  
C1q 
C1q is a 460 kDa molecule and is the first subcomponent of the classical complement 
pathway. It is composed of 18 polypeptide chains (six A, six B and six C chains). The A chain 
(223 residues), B chain (226 residues) and C chain (217 residues) consist of a short N-
terminal region (~ 3 to 9 residues), collagen-like region (CLR; ~ 81 residues) and C-terminal 
globular head region (gC1q; ~ 135 residues) (Sellar et al., 1991). 
There are 4 cysteine residues at positions (numbering as per B chain) 4, 135, 154 and 171. 
The cysteine residue at position 4 is involved in inter-chain disulphide bridge, leading to 
formation of A-B and C-C sub-units. The other three cysteine residues are thought to form 
one intra-chain disulphide bond (6 A-B and 3 C-C dimer subunits). The CLR region of A and B 
chains of A-B subunit along with CLR region of C chain of C-C subunit for a triple-helix ABC-
CBA unit and three such units associate to form the hexameric  structure of C1q (Reid and 
Porter, 1976; Kishore and Reid, 1999; Kishore et al., 2003). C1q is a pattern-recognition 
receptor (PRR) and its structure resembles other PRRs such as MBL, ficolin, surfactant 
protein (SP)-A, SP-D (Nayak et al., 2010).  
The structure of C1q shows a β sandwich fold with jelly roll topology, similar to that 
described for tumour necrosis factor and gC1q family, leading to recognition of C1q/TNF 
superfamily (Kishore et al., 2004). The structure of gC1q also shows presence of a Ca2+ at the 
top of the assembly (Gaboriaud et al., 2012). The gC1q module is found in a number of other 
non-complement proteins (Kishore and Reid, 2000) such as collagens type VIII and type X, 
Acrp-30 (adipose-specific protein), saccular collagen (found in inner ear), elastin microfibril 
interface-located protein (extracellular matrix glycoprotein), precerebellin and multimerin 
(Yamaguchi et al., 1989; Ninomiya et al., 1986; Scherer et al., 1995; Hu et al., 1996; Davis et 
al., 1995; Doliana et al., 1999; Urade et al., 1991; Hayward et al., 1995).   
Apart from classical complement pathway activation (ligands being IgG, IgM, β-amyloid), 
some of the other functions include immune-complex clearance, bacterial cells clearance, 
binding and inactivation of viruses, induction of pro-inflammatory cytokines, clearance of 
apoptotic cells and coagulation (Nayak et al., 2010). C1q is also implicated in 
neuroinflammation, scrapie pathogenesis, T-cell and B-cell development, pregnancy and 
central nervous system (CNS) development (Shastri et al., 2013). 
Some of the disorders associated with aberrant C1q activity are listed in Table 1. 
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Table 1: List of disorders associated with aberrant C1q activity (Shastri et al, 2013) 
Diseases Role/Involvement of C1q 
Systemic lupus erythematosus Deficiency of C1q 
Autoantibodies against C1q and globular heads of C1q 
Nephropathy Deposition of C1q in mesangium or glomerulus of 
kidneys leading to nephritis or nephrotic syndrome 
Alzheimer’s disease Dual role of neuroprotection and neurodegeneration 
Familial dementias Complement pathway activation 
Prion diseases Uptake and recognition of prion protein 
Traumatic brain injury Upregulation of C1q 
Cerebral malaria Increased C1q activity & formation of MAC 
Fungal infections like Aspergillosis Increased C1q production by macrophages 
Multiple sclerosis Priming of microglia 
Parkinson’s disease Uptake of neuromelanin by C1q-positive microglia 
Huntington’s disease Pathological deposition in neuropathological studies 
Schizophrenia Upregulation of complement activity 
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Figure 2: Association of classical and alternative pathway of the complement system with β-amyloid 
(Aβ). C1q and C3b bind to fibrillar Aβ1 (see below for image reference) and activate the classical and 
alternative pathways respectively while C4 is activated by non-fibrillar Aβ2 (see below for image 
reference). This activation of complement pathway leads to formation of anaphylotoxins C3a and 
C5a as well as membrane attack complex (MAC). These anaphylotoxins are involved in the activation 
of microglia which leads to secretion of pro-inflammatory cytokines like tumour necrosis factor-α 
(TNF-α) and interleukin 1-β (IL-1β). MAC deposition on neurons leads to neuronal apoptosis. 
Complement regulators for classical pathway involved are complement receptor 1 (CR1) and C4b-
binding protein (C4BP), alternative pathway is factor H, and membrane attack complex (MAC) is 
stabilised by clusterin and CD59. 
                                                          
1
 Image from the RCSB PDB (www.pdb.org) of PDB ID 2BEG (T. Luhrs, C. Ritter, M. Adrian, D. Riek-Loher, B. 
Bohrmann, H. Dobeli, D. Schubert, R.Riek (2005) 3D structure of Alzheimer’s amyloid-beta (1-42) fibrils 
Proc.Natl.Acad.Sci.USA 102: 17342-17347). 
 
2
 Image from the RCSB PDB (www.pdb.org) of PDB ID 1Z0Q (S. Tomaselli, V. Esposito, P. Vangone, N. A. van 
Nuland, A. M. Bonvin, R. Guerrini, T. Tancredi, P. A. Temussi, D. Picone (2006) The alpha-to-beta 
conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a 
step by step conformational analysis suggests the location of beta conformation seeding Chembiochem 7: 257-
267). 
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Table 2: Known ligands of C1q (adapted from Kishore and Reid, 2000) 
Immunoglobulins IgG (IgG3, 
IgG1, IgG2) 
Globular head region B of C1q is the main IgG-binding molecule for 
C1q. Weak interaction is observed in the binding of C1q to Fc 
region (non-aggragated) but the interaction increases thousand-
fold when the simulation on immune complexes (closely spaced Fc 
portions) occurs. The Fab portion also interacts with C1q. 
 
 IgM Globular head region C of C1q is most specific in binding to IgM. 
Monomeric form of IgM does not bind C1q. The hexameric and 
pentameric forms of IgM bind to C1q with the efficiency of former 
being 100 times more than the latter in activation of complement 
system. 
 
Non-
immunoglobulins 
CRP C1q binds to CRP through the globular head region with 
pentameric form of CRP. CRP binds to nuclear debris and by 
binding to C1q, helps in clearance of chromosomal material from 
necrotic cells.  
 
 SAP SAP binding to C1q helps in preventing antinuclear autoimmunity 
by helping in controlling degradation of chromatin. 
 
 PTX3 PTX3 interacts with C1q via the globular head region and interacts 
with the tetrameric C1q-C1r2-C1s2. This helps in uptake of 
apoptotic cells by phagocytes and also amplifies response to fungal 
pathogens. 
 
 Decorin Decorin binds to the neck region of C1q and downregulates 
proinflammatory effects of C1q. 
 
 Fibronectin Fibronectin binds to C1q and play a role in formation of 
cryoglobulins and clearance of immune complexes. 
 
 Lactoferrin Lactoferrin binds to C1q and helps in uptake of Streptococci. 
 
 Calreticulin Calreticulin binding with C1q helps in apoptotic cell recognition and 
uptake as well as elimination of immune complexes. 
 
 SIGN-R1 C1q binds to SIGN-R1 which in-turn binds to Streptococcus 
pneumonia and causes C3d deposition on the bacteria leading to 
bacterial killing.  
 
Viruses HTLV-1 Interaction and binding of C1q to HTLV-1 inhibits its infectivity 
 
 HIV-1 Interaction and binding of HIV-1 by C1q results in viral 
neutralisation and activation of classical complement pathway  
 
Cells Neutrophils Enhances phagocytosis and chemotaxis 
 
 Monocytes Enhances phagocytosis 
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 Platelets Induces expression of adhesion molecules 
 
 B cells Enhances secretion of Immunoglobulins 
 
 Fibroblasts Enhances phagocytosis and chemotaxis 
 
Polyanions Heparin Heparin binds to C1q and inhibits activation of classical pathway 
 
 Cardiolipin Binding of cardiolipin to C1q occurs via gC1q región, significant in 
ischaemic myocardium reperfusion injury 
 Lipopolysa-
ccharide 
Gram-negative bacteria actívate complement pathway in an 
antibody-independent manner by binding via LPS on bacteria (gC1q 
región is involved in this binding and recognition)  
 
 Cardiolipin Binding of cardiolipin to C1q occurs via gC1q región, significant in 
ischaemic myocardium reperfusion injury 
 Chondroitin 
suplate 
Secreted by activated platelets, it activates complement system 
and is significant in myocardial ischaemia 
 
 Phosphati-
dylserine 
Phosphatidylserine provides “eat-me” signal on apoptotic cells and 
helps in apoptotic cell clearance  
 
 DNA C1q binds to DNA via gC1q región and is involved in apoptotic cell 
clearance and play a key role in flare-ups as well as pathogenesis of 
SLE 
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Structure of globular head region of C1q and modularity 
 
 
Figure 3: Structural organization of the C1q molecule. C1q (460 kDa) is composed of 18 polypeptide chains (6A, 
6B and 6C). (a) The A, B and C chains each have a short N-terminal region (containing a half-cystine residue 
involved in interchain disulfide bond formation), followed by a collagen region (CLR) of w81 residues and a C-
terminal globular region (gC1q domain) ofw135 residues. (b) The interchain disulfide bonding yields 6A–B 
dimer subunits and 3C-C dimer subunits. The triple-helical collagen region in the A and B chains of an A–B 
subunit, together with one of the C-chains present in a C–C subunit, form a structural unit (ABC–CBA), which is 
held together by both covalent and non-covalent bonds (c). Three of these structural units associate, via strong 
non-covalent bonds in the fibril-like central portion, to yield the hexameric C1q molecule that has a tulip-like 
structure. Image and legend Reference: Kishore U, Gaboriaud C, Waters P, Shrive A, Greenhough, T, Reid, KBM, 
Sim RB, Arlaud G; Trends in Immunology; vol. 25, No. 10, (2004). 
The globular head domain of C1q (gC1q) is the C-terminal region composed of its A, B and C 
chains (ghA, ghB and ghC respectively). The gC1q domain has a heterotrimeric organisation 
and each of the three modules of gC1q can bind ligands independently (Kishore et al, 2003). 
ghA can bind heat-aggregated IgG and IgM as well as HIV-1 gp41-derived loop peptide. ghB 
binds to heat-aggregated IgG as well as β-amyloid peptide. ghC shows preferential binding 
to IgM as well as HTLV-1 gp21 peptide. In addition, ghB shows a predominance of positive 
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charges on its external face whereas ghA and ghC show a combination of basic and acidic 
residues on their external face (Appendix 3; Kishore et al, 2004). 
Thus, the presence of modularity of the heterotrimeric assembly coupled with surface 
charge pattern differences and spatial orientation of the globular heads, it adds to the 
flexibility and versatility of the gC1q module (Kishore et al, 2004). 
 
 
Globular Head of the Complement System Protein C1q  
Protein chains are coloured from the N-terminal to the C-terminal using a rainbow (spectral) colour gradient. 
Figure 4: Image from the RCSB PDB (www.rcsb.org) of PDB ID 1PK6; Gaboriaud, C., Juanhuix J., Gruez, A., 
Lacroix, M., Darnault, C., Pignol, D., Verger, D., Fontecilla-Camps, J.C., Arlaud, G.J. (2003); The crystal structure 
of the globular head of complement protein C1q provides a basis for its versatile recognition properties. 
J.Biol.Chem. 278: 46974-46982. 
The 3-D structure of gC1q revealed a diameter of 50 Angstrom with the N-terminal and C-
terminal regions of each sub-unit emerging at the base of the trimer, very close to one 
another. gC1q subunits were found to be arranged clockwise in the order A, B, C when 
viewed from the superior angle (top view) (Gaboriaud et al., 2011). The B subunit (ghB) was 
found to lie on the outer part of the molecule and ghA and ghC were positioned on the 
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inside. A free cysteine residue is conserved in gC1q domain and in addition, each subunit of 
C1q contains two other cysteine residues in disulphide bonds.  
Binding of C1q to IgG1 and PTX3 is considered to be highly electrostatic in nature as in vitro 
studies have shown that the binding is highly sensitive to the ionic strength of the binding 
buffer (presence of 1.2 M NaCl abolishes interaction to a large extent) (Roumenina et al, 
2006). The exposed Ca2+ near the apex of gC1q influences interaction of C1q with IgG1, CRP 
and PTX3. Mutational analysis studies have shown that ArgB114, ArgB129 and HisB117are central 
to interaction of gC1q with IgG1. TyrB175 and LysC170 are central to C1q-PTX3 interaction 
(Roumenina et al, 2006). 
IgG and IGM binding sites on gC1q are distinct but may overlap and in vitro studies have also 
confirmed the importance of ArgB108 and ArgB109 in initial recognition and final binding of 
gC1q wth IgG and IgM. LysA200 and LysC170 were also found to be central to C1q binding with 
IgG and IgM (Gadjeva et al, 2008).   
Prion diseases or transmissible spongiform encephalopathies are a group of 
neurodegenerative disorders that are infective and are known to occur in humans, cattle 
and other livestock such as sheep and deer. Creutzfeldt-Jakob disease (CJD), fatal familial 
insomnia and kuru are known prion diseases in humans with the variant form of CJD being 
transmissible from meat infected with prion disease. The fibrillar form of normally present 
prion proteins, referred to as PrPSc (scrapie-associated prion protein), accumulates in the 
neurodegenerative plaques – these are cytotoxic are form protease-resistant fibrils and 
oligomers. Infection is propagated via oral ingestion, following which the PrPSc penetrates 
the intestinal epithelium, facilitated by proliferation involving follicular dendritic cells, 
enters the lymphatic system and finally makes its way into the CNS. C1q interacts with PrP 
and has been shown to involve gC1q region and help in uptake of PrP as well as activation of 
classical complement pathway.  (Mitchell, 2013; Mitchell et al., 2007) 
Pentraxins are a family of evolutionary conserved proteins pattern recognition proteins 
containing the carboxy-terminal 200 amino acid pentraxin domain. Based on the length of 
their structure, these are classified into short and long pentraxins. The short pentraxins are 
CRP and SAP which are acute-phase proteins. PTX3 is a long pentraxin and produced most 
abundantly by dendritic cells. PTX3 interacts and recognises selected pathogens such as 
gram-negative bacteria and Aspergillus fumigatus, growth factors, oophorous matrix, 
apoptotic cells and extracellular matrix components. PTX3 interacts with C1q via gC1q 
region and has also been shown to interact with recombinant globular heads of human C1q 
along with TyrB175 and LysC170 being central to this interaction (Nauta et al, 2003; Roumenina 
et al, 2006; Kishore and Reid, 2007). 
A lot of work has been done on mouse C1q in the field of nephritis (Trouw et al., 2004a; 
Trouw et al., 2004b; Trouw et al., 2003), systemic lupus erythematosis (Hogarth et al., 1996; 
Trinder et al., 1995; Cortes-Hernandez et al., 2004), Alzheimer’s disease (Fonesca et al., 
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2011) and prion diseases (Klein, et al., 2001; Mabbott et al., 2001; Mitchell et al., 2007). In 
order to understand modularity of gC1q region of mouse C1q and to generate useful 
reagents for mouse work, we have expressed these recombinant individual heads of mouse 
C1q. We have examined their interaction with heat-aggregated mouse IgG and IgG isotypes, 
mouse IgM, mouse pentraxin-3 (PTX-3) and prion peptide.    
 
 
Materials and methods 
RNA extraction and cDNA synthesis 
Total RNA was prepared from mouse spleen using TRIzol reagent (Invitrogen Life 
Technologies), according to the manufacturer’s instructions. 10 µg of total RNA was 
digested RNase-free DNase I (Promega), extracted once with phenol/chloroform/isoamyl 
alcohol (25/24/1). RNA was precipitated from the aqueous phase, washed with ethanol and 
finally re-dissolved in water. 
For cDNA synthesis, one μg of RNA was reverse transcribed into cDNA according to the 
instruction manual of superscript tm first strand cDNA synthesis system for RT-PCR 
(Invitrogen). Briefly, 1 μl of Oligo(dT)23 anchored primers (Sigma) were added to 1μg of RNA 
in a final volume of 11.5 μl. The reaction mixture was incubated for 10 minutes at 70°C. 
After that, the temperature was decreased to 45°C and 1 μl superscript II, 2 μl RT buffer 
(10x), 2 μl MgCl2, 2 μl of 0.1M DTT, 1 μl dNTPs (10mM) and 0.5 μl RNasin (Promega) were 
added and the reaction mixer was re-incubated for another 60 minutes at 45°C, followed by 
10 minutes incubation at 70°C. Finally, the temperature was dropped to 4°C. After cDNA 
preparation, the template RNA was digested using one μl of RNase H (Promega) and 
incubation at 37°C for 20 minutes.          
 
Construction of vectors for the extracellular expression of full length recombinant mouse 
C1q  
The plasmid used for protein expression was pSectag-B (New England Biolabs, Beverley, 
MA). The primers used to amplify the DNA sequences of each of the globular heads were: 
C1qA forward primer (FP) 5’-GGGGAATTCAGGGACCAGCCCCGGCC-3’ and C1qA reverse 
primer (RP) 3’- GGGAAGCTTTCAGGCCGAGGGGAAAATGAGGAAT-5’; C1qB FP 5’-
GGGGAATTCGGGGCTACACAGAAAGTCGCCT-3’ and C1qB RP 3’-
GGGAAGCTTTTACGCATCCATGTCAGGGAAAAGCA-5’; C1qC FP 5’-
GGGGAATTCAAACAGAAGCACCAGTCGGTATTCACA-3’ and C1qC RP 3’- 
GGGAAGCTTCTAGTCGGGAAACAGTAGGAAACCA-5’. Plasmid pMal-c was double digested 
with HINDIII and EcoRI and each PCR product was cloned as a HindIII-EcoRI fragment. The 
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polypeptide sequence thus expressed corresponded to residues of C1qA, of C1qB and of 
C1qC. The recombinant vectors were named as pAS-A, pAS-B and pAS-C, respectively. 
 
Plasmid pMal-c 
The vector pMAL-c is designed to produce maltose-binding protein (MBP) fusions, where 
the protein of interest can be cleaved from MBP with a specific protease called as Factor Xa. 
The MBP fusion proteins formed are expressed in the cytoplasm, and for purification 
purposes, the MBP is engineered to bind tightly to amylose resin column. A gene can be 
inserted in the restriction site of vector, in the translational reading frame of malE gene. The 
malE gene encodes for MBP. This provides for the fusion protein to be purified using 
amylose resin affinity chromatography and can then later be cleaved from MBP using the 
protease Factor Xa. 
 
Figure 5a: Vector pMalc 
The system uses the method of “tac” promoter and carries LacZ gene which codes for the 
Lac repressor. This keeps the expression from Ptac low in the absence of IPTG (induction). 
The vector consists of multiple cloning sites containing restriction sites for cloning 
fragments. Blunt-ended subcloning method was implemented.   
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Figure 5b: Vector pMalc 
Full-length mouse C1q A chain 
 
ATGGAGACCTCTCAGGGATGGCTGGTGGCCTGTGTGCTGACCATGACCCTAGTATGGACAGTGGCTGAAGATGTC
TGCCGAGCACCCAACGGGAAGGATGGGGCTCCAGGAAATCCTGGCCGCCCGGGGAGGCCGGGTCTCAAAGGAGAG
AGAGGGGAGCCAGGAGCTGCTGGCATCCGGACTGGTATCCGAGGTTTTAAAGGAGACCCAGGGGAATCTGGCCCC
CCTGGCAAACCTGGCAATGTGGGGCTCCCAGGTCCCAGTGGTCCCCTGGGGGACAGCGGCCCCCAAGGACTGAAG
GGCGTGAAAGGCAATCCAGGCAATATCAGGGACCAGCCCCGGCCAGCTTTCTCAGCCATTCGGCAGAACCCAATG
ACGCTTGGCAACGTGGTTATCTTTGACAAGGTCCTCACCAACCAGGAGAGTCCATACCAGAACCACACGGGTCGC
TTCATCTGTGCAGTGCCCGGCTTCTATTACTTCAACTTCCAAGTGATCTCCAAGTGGGACCTTTGTCTGTTTATC
AAGTCTTCCTCCGGGGGCCAGCCCAGGGATTCCCTGAGTTTCTCTAACACCAACAACAAGGGGCTCTTTCAGGTG
TTAGCAGGGGGCACCGTGCTTCAGCTGCGACGAGGGGACGAGGTGTGGATCGAAAAGGACCCCGCAAAGGGTCGC
ATTTACCAGGGCACTGAAGCCGACAGCATCTTCAGCGGATTCCTCATTTTCCCCTCGGCCTGA 
Key 
        - signal peptide                              - collagen-like region                           -globular head 
region 
Figure 6a. Sequence of full-length mouse C1q A chain 
 
Full-length C1q B chain 
 
ATGAAGACACAGTGGGGTGAGGTCTGGACACACCTGTTACTGCTGCTTCTAGGTTTTCTCCATGTGTCCT 
GGGCCCAAAGCAGCTGCACCGGGCCCCCTGGCATCCCTGGCATCCCTGGGGTCCCTGGGGTTCCTGGCTC 
TGATGGCCAACCAGGCACTCCAGGGATAAAGGGGGAGAAAGGGCTCCCTGGACTGGCTGGAGACCTTGGT 
GAGTTTGGAGAGAAAGGGGACCCAGGGATCCCTGGGACTCCAGGCAAAGTTGGCCCTAAGGGTCCCGTCG 
GCCCTAAGGGTACTCCAGGCCCCTCTGGACCCCGCGGTCCCAAAGGCGATTCTGGGGACTACGGGGCTAC 
ACAGAAAGTCGCCTTCTCTGCCCTGAGGACCATCAACAGCCCCTTGCGACCGAACCAGGTCATTCGCTTC 
GAAAAGGTGATCACCAACGCGAACGAGAACTATGAGCCACGCAACGGCAAGTTCACCTGCAAGGTGCCTG 
GCCTCTACTACTTCACCTATCATGCCAGCTCCCGGGGCAACCTGTGTGTGAATCTCGTTCGTGGCCGCGA 
TCGGGACAGCATGCAGAAAGTAGTCACCTTCTGTGACTATGCCCAGAACACCTTCCAGGTGACCACAGGT 
GGGGTAGTCTTGAAGCTAGAGCAAGAGGAGGTTGTTCACCTGCAGGCCACAGACAAGAACTCCCTCCTGG 
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GCATTGAGGGTGCCAACAGCATCTTCACTGGCTTTCTGCTTTTCCCTGACATGGATGCGTAA 
 
Key 
        - signal peptide                              - collagen-like region                           -globular head 
region 
Figure 6b. Sequence of full-length mouse C1q B chain 
 
Full length C1q C chain 
 
ATGGTCGTTGGACCCAGTTGCCAGCCTCCATGTGGACTTTGCCTGCTGCTGCTGTTTCTTCTGGCCCTAC 
CACTCAGGAGCCAGGCCAGCGCTGGCTGCTATGGGATCCCAGGGATGCCAGGCATGCCGGGGGCCCCTGG 
GAAGGACGGGCATGATGGACTCCAGGGGCCCAAGGGAGAGCCAGGAATCCCAGCCGTCCCTGGGACCCGA 
GGACCCAAGGGTCAGAAGGGCGAGCCTGGCATGCCTGGCCACCGTGGGAAAAATGGCCCCAGGGGGACCT 
CAGGGTTGCCAGGGGACCCAGGCCCCAGGGGGCCTCCGGGGGAGCCAGGTGTGGAGGGCCGATACAAACA 
GAAGCACCAGTCGGTATTCACAGTCACCCGGCAGACCACCCAGTACCCAGAGGCCAACGCCCTCGTCAGG 
TTCAACTCTGTGGTCACCAACCCTCAGGGGCATTACAACCCAAGCACAGGGAAGTTCACCTGTGAAGTGC 
CGGGCCTCTACTACTTCGTCTACTACACATCGCATACGGCCAACCTGTGCGTGCACCTGAACCTCAACCT 
TGCCAGGGTGGCCAGCTTCTGCGACCACATGTTCAACAGCAAGCAGGTCAGCTCCGGAGGAGTCCTCCTG 
CGGCTCCAGAGGGGCGATGAGGTGTGGCTATCAGTCAATGACTACAATGGCATGGTGGGCATAGAGGGCT 
CCAACAGCGTCTTCTCTGGTTTCCTACTGTTTCCCGACTAG 
 
Key 
        - signal peptide                              - collagen-like region                           -globular head 
region 
Figure 6c. Sequence of full-length mouse C1q C chain 
 
 
Primers designed 
 
Key: F: Forward primer; R: Reverse primer; Tm: Melting temperature in degree Celsius; 
         bp: Base pairs; restriction enzyme used is underlined 
 
Mouse C1qA 
 
F (HINDIII): GGGAAGCTTGAAGATGTCTGCCGAGCACCC  
Tm=58       GC=62%, AT=38%   bp=21 
 
R (EcoRI): GGGGAATTCTCAGGCCGAGGGGAAAATGAGGAAT  
Tm=59   GC= 52%, AT= 48%   bp=25              
 
 
Mouse C1qB 
 
F (HINDIII): GGGAAGCTTCAAAGCAGCTGCACCGGGC   
Tm=58     GC=68%, AT=32%  bp=19                 
 
R (EcoRI): GGGGAATTCTTACGCATCCATGTCAGGGAAAAGCA    
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Tm=58   GC=46%, AT=54%   bp=26 
 
 
Mouse C1qC 
 
F (HINDIII): GGGAAGCTTAGCGCTGGCTGCTATGGGATC    
Tm=58   GC=62%, AT=38%   bp=21 
 
R (EcoRI): GGGGAATTCCTAGTCGGGAAACAGTAGGAAACCA     
Tm=58   GC=48%, AT=52%   bp=25 
 
 
Construction of vectors for the intracellular expression of globular head region of mouse 
C1q A, B and C chains as fusion proteins 
The plasmid used for protein expression was pMal-c (New England Biolabs, Beverley, MA), 
which codes for maltose-binding protein under the Ptac promoter (de Boer, Comstock, 1983, 
PNAS). The primers used to amplify the DNA sequences of each of the globular heads were: 
ghA forward primer (FP) 5’-GGGGAATTCAGGGACCAGCCCCGGCC-3’ and ghA reverse primer 
(RP) 3’-GGGAAGCTTTCAGGCCGAGGGGAAAATGAGGAAT-5’; ghB FP 5’-
GGGGAATTCGGGGCTACACAGAAAGTCGCCT-3’ and ghB RP 3’-
GGGAAGCTTTTACGCATCCATGTCAGGGAAAAGCA-5’; ghC FP 5’-
GGGGAATTCAAACAGAAGCACCAGTCGGTATTCACA-3’ and ghC RP 3’- 
GGGAAGCTTCTAGTCGGGAAACAGTAGGAAACCA-5’. Plasmid pMal-c was double digested 
with EcoRI and HindIII and each PCR product was cloned as a EcorI-HindIII fragment. The 
polypeptide sequence thus expressed corresponded to residues of ghA, of ghB and of ghC. 
The recombinant vectors linked to MBP were named as , and  , respectively. 
 
Globular head region of C1q A chain 
 
ATGGAGACCTCTCAGGGATGGCTGGTGGCCTGTGTGCTGACCATGACCCTAGTATGGACAGTGGCTGAAGATGTC
TGCCGAGCACCCAACGGGAAGGATGGGGCTCCAGGAAATCCTGGCCGCCCGGGGAGGCCGGGTCTCAAAGGAGAG
AGAGGGGAGCCAGGAGCTGCTGGCATCCGGACTGGTATCCGAGGTTTTAAAGGAGACCCAGGGGAATCTGGCCCC
CCTGGCAAACCTGGCAATGTGGGGCTCCCAGGTCCCAGTGGTCCCCTGGGGGACAGCGGCCCCCAAGGACTGAAG
GGCGTGAAAGGCAATCCAGGCAATATCAGGGACCAGCCCCGGCCAGCTTTCTCAGCCATTCGGCAGAACCCAATG
ACGCTTGGCAACGTGGTTATCTTTGACAAGGTCCTCACCAACCAGGAGAGTCCATACCAGAACCACACGGGTCGC
TTCATCTGTGCAGTGCCCGGCTTCTATTACTTCAACTTCCAAGTGATCTCCAAGTGGGACCTTTGTCTGTTTATC
AAGTCTTCCTCCGGGGGCCAGCCCAGGGATTCCCTGAGTTTCTCTAACACCAACAACAAGGGGCTCTTTCAGGTG
TTAGCAGGGGGCACCGTGCTTCAGCTGCGACGAGGGGACGAGGTGTGGATCGAAAAGGACCCCGCAAAGGGTCGC
ATTTACCAGGGCACTGAAGCCGACAGCATCTTCAGCGGATTCCTCATTTTCCCCTCGGCCTGA 
Key 
         - signal peptide                             - collagen-like region                           -globular head 
region 
Figure 7a. Sequence of globular head region of mouse C1q A chain 
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Globular head region of C1q B chain 
 
ATGAAGACACAGTGGGGTGAGGTCTGGACACACCTGTTACTGCTGCTTCTAGGTTTTCTCCATGTGTCCT 
GGGCCCAAAGCAGCTGCACCGGGCCCCCTGGCATCCCTGGCATCCCTGGGGTCCCTGGGGTTCCTGGCTC 
TGATGGCCAACCAGGCACTCCAGGGATAAAGGGGGAGAAAGGGCTCCCTGGACTGGCTGGAGACCTTGGT 
GAGTTTGGAGAGAAAGGGGACCCAGGGATCCCTGGGACTCCAGGCAAAGTTGGCCCTAAGGGTCCCGTCG 
GCCCTAAGGGTACTCCAGGCCCCTCTGGACCCCGCGGTCCCAAAGGCGATTCTGGGGACTACGGGGCTAC 
ACAGAAAGTCGCCTTCTCTGCCCTGAGGACCATCAACAGCCCCTTGCGACCGAACCAGGTCATTCGCTTC 
GAAAAGGTGATCACCAACGCGAACGAGAACTATGAGCCACGCAACGGCAAGTTCACCTGCAAGGTGCCTG 
GCCTCTACTACTTCACCTATCATGCCAGCTCCCGGGGCAACCTGTGTGTGAATCTCGTTCGTGGCCGCGA 
TCGGGACAGCATGCAGAAAGTAGTCACCTTCTGTGACTATGCCCAGAACACCTTCCAGGTGACCACAGGT 
GGGGTAGTCTTGAAGCTAGAGCAAGAGGAGGTTGTTCACCTGCAGGCCACAGACAAGAACTCCCTCCTGG 
GCATTGAGGGTGCCAACAGCATCTTCACTGGCTTTCTGCTTTTCCCTGACATGGATGCGTAA 
 
Key 
        - signal peptide                              - collagen-like region                           -globular head 
region 
Figure 7b. Sequence of globular head region of mouse C1q B chain 
 
Globular head region of C1q C chain 
 
ATGGTCGTTGGACCCAGTTGCCAGCCTCCATGTGGACTTTGCCTGCTGCTGCTGTTTCTTCTGGCCCTAC 
CACTCAGGAGCCAGGCCAGCGCTGGCTGCTATGGGATCCCAGGGATGCCAGGCATGCCGGGGGCCCCTGG 
GAAGGACGGGCATGATGGACTCCAGGGGCCCAAGGGAGAGCCAGGAATCCCAGCCGTCCCTGGGACCCGA 
GGACCCAAGGGTCAGAAGGGCGAGCCTGGCATGCCTGGCCACCGTGGGAAAAATGGCCCCAGGGGGACCT 
CAGGGTTGCCAGGGGACCCAGGCCCCAGGGGGCCTCCGGGGGAGCCAGGTGTGGAGGGCCGATACAAACA 
GAAGCACCAGTCGGTATTCACAGTCACCCGGCAGACCACCCAGTACCCAGAGGCCAACGCCCTCGTCAGG 
TTCAACTCTGTGGTCACCAACCCTCAGGGGCATTACAACCCAAGCACAGGGAAGTTCACCTGTGAAGTGC 
CGGGCCTCTACTACTTCGTCTACTACACATCGCATACGGCCAACCTGTGCGTGCACCTGAACCTCAACCT 
TGCCAGGGTGGCCAGCTTCTGCGACCACATGTTCAACAGCAAGCAGGTCAGCTCCGGAGGAGTCCTCCTG 
CGGCTCCAGAGGGGCGATGAGGTGTGGCTATCAGTCAATGACTACAATGGCATGGTGGGCATAGAGGGCT 
CCAACAGCGTCTTCTCTGGTTTCCTACTGTTTCCCGACTAG 
 
Key 
        - signal peptide                              - collagen-like region                           -globular head 
region 
Figure 7c. Sequence of globular head region of mouse C1q C chain 
 
 
 
Primers designed 
 
Key: F: Forward primer; R: Reverse primer; Tm: Melting temperature in degree Celsius; 
         bp: Base pairs; restriction enzyme used is underlined 
 
Mouse ghA 
 
F (EcoRI): GGGGAATTCAGGGACCAGCCCCGGCC             
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Tm=59   GC=82%, AT=18%   bp=17 
 
R (HINDIII): GGGAAGCTTTCAGGCCGAGGGGAAAATGAGGAAT  
Tm=59   GC= 52%, AT= 48%   bp=25              
 
 
Mouse ghB 
 
F (EcoRI): GGGGAATTCGGGGCTACACAGAAAGTCGCCT   
Tm=59     GC=59%, AT=41%   bp=22 
 
R (HINDIII): GGGAAGCTTTTACGCATCCATGTCAGGGAAAAGCA    
Tm=58   GC=46%, AT=54%  bp=26 
 
 
 
Mouse ghC 
 
F (EcoRI): GGGGAATTCAAACAGAAGCACCAGTCGGTATTCACA    
Tm=58   GC=44%, AT=56%   bp=27 
 
R (HINDIII): GGGAAGCTTCTAGTCGGGAAACAGTAGGAAACCA       
Tm=58   GC=48%, AT=52%   bp=25 
 
Oligonucleotide primers were planned to contain 20–40 nucleotides in length and ideally 
have a GC content of 40–60%.  
 
 
Polymerase chain reaction 
Polymerase chain reaction (PCR) was first performed for full-length mouse C1q A, B and C 
chains using cDNA extracted from mouse spleen as template. The following reaction mixture 
was set up: 
 
5X NEB Phusion® buffer      10 μl 
10mM dNTPs          1 μl 
Template DNA (cDNA)        1 μl 
NEB Phusion® DNA Polymerase    0.5 μl 
10μM Forward primer     2.5 μl 
10μM Reverse primer      2.5 μl 
PCR grade water    32.5 μl 
 
Total reaction volume       50 μl 
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A ‘mastermix’  was set up which contained the following (n):  
5X NEB Phusion® buffer      10 μl 
10mM dNTPs          1 μl 
Template DNA (cDNA)        1 μl 
NEB Phusion® DNA Polymerase    0.5 μl 
PCR grade water    32.5 μl 
 
Total reaction volume       45 μl 
 
The template cDNA used was diluted 1:10 with PCR-grade water. 
Thus, with 3 different forward and reverse primers required (n=3), a total ‘mastermix’ 
solution of the above was calculated to be n+1 (=4) plus a negative control was calculated as 
below: 
5X NEB Phusion® buffer      50 μl 
10mM dNTPs          5 μl 
Template DNA (cDNA)        5 μl 
NEB Phusion® DNA Polymerase    2.5 μl 
PCR grade water    162.5 μl 
 
Total reaction volume       225 μl 
 
Then, to each Eppendorf tube, 45 μl of the above mixture was added. The tubes were 
labelled as mC1qA, mC1qB, mC1qC and negative control. 
To the appropriate tubes, the required Forward and Reverse primers for mC1qA, mC1qB 
and mC1qC were added (none to the negative control). A PCR was then set up. 
 
PCR conditions 
The reaction mixture containing the appropriate primers were added to PCR tubes and 
placed in PCR machine. The lid was heated to 120°C. Followed by 30 cycles of 98°C for 30 
seconds, 58°C for 30 seconds and 72°C for 10 minutes. Then, the reaction mixture was 
stored at 4°C. 5 μl of the reaction mixture was then pipetted and run on a 0.7% agarose gel. 
Initial Denaturation  98°C  30 seconds 
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30 cycles   58°C  30 seconds 
Final extension   72°C  10 minutes 
Store    4°C  Indefinitely 
 
Agarose gel 
0.35 grams of DNA grade agarose was measured and dissolved in 50 ml of autoclaved water. 
The melting temperature of agarose is quite high and thus, this has to be dissolved by 
heating in microwave. Once it dissolves completely and begins to cool down, 5 μl of 
ethidium bromide is added to this mixture. Ethidium bromide intercalates with DNA strands 
and helps in detection of DNA by being visible under ultraviolet (UV) radiation exposure. 
However, ethidium bromide must be handled with gloves ONLY since it is carcinogenic. 
Then, this mixture is poured onto plate with comb so as to form wells. Once the mixture 
cools down, it hardens and the gel is ready to be used. 5 μl of PCR sample is added to 5 μl of 
loading dye (30% glycerol; 0.25% bromophenol blue), mixed well and loaded onto the wells. 
1X TBE buffer (10.8 grams Tris/5.5 grams Borate/4ml of 0.5M EDTA) is added to fill up the 
electrophoresis tank. The gel is run at 80 volts for 60 minutes. The agarose gel is visualised 
under UV radiation. 
 
PCR for mghA, mghB and mghC 
As above, this time the PCR product of full-length mC1qA, mC1qB and mC1qC was used as 
template to extract the globular head regions. 
A ‘mastermix’ of the following was set-up: 
 
5X NEB Phusion® buffer      50 μl 
10mM dNTPs          5 μl 
NEB Phusion® DNA Polymerase    2.5 μl 
PCR grade water    162.5 μl 
 
Total reaction volume       220 μl 
 
44 μl of the above mixture was added to each Eppendorf tube labelled as mghA, mghB, 
mghC and negative control. 
To the appropriate tubes, 1 μl of respective template DNA from the earlier PCR was added 
along with the required Forward and Reverse primers (2.5 μl of each).  
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The final concentration of each primer in a reaction using Phusion DNA Polymerase® was 
recommended to be 0.2–1 μM, while 0.5 μM was recommended as optimal. 
 
Restriction enzyme digestion of PCR products and plasmid pMalC 
The PCR products as well as the plasmid were subjected to restriction enzyme digestion. The 
enzymes used to perform the digestion were EcoRI and HINDIII. The following reaction 
mixture using the appropriate buffer was set up: 
Reaction 1 (PCR products) 
PCR product   10 μl 
EcoRI     1 μl 
HINDIII     1 μl 
10X NEB® Buffer 2   3 μl 
PCR grade water 15 μl 
 
Total reaction volume 30 μl 
 
Therefore, a ‘mastermix’ of the following (n=4 including negative control) was set up (n+1): 
EcoRI     5 μl 
HINDIII     5 μl 
10X NEB® Buffer 2  15 μl 
PCR grade water  75 μl 
 
Total reaction volume  100 μl 
 
20 μl of this ‘mastermix’ was added to each Eppendorf tube labelled as mghA, mghB, mghC 
and negative control. 
To the appropriate tubes, 10 μl of respective PCR product was added. 
 
Reaction 2 (Plasmid-pMalC) 
pMalC plasmid DNA 10 μl 
EcoRI     1 μl 
HINDIII     1 μl 
10X NEB® Buffer 2   3 μl 
PCR grade water 15 μl 
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Total reaction volume 30 μl 
 
Ligation of digested PCR products and digested plasmid 
The PCR products and plasmid each having undergone restriction enzyme digestion is first 
heat-inactivated. In order to heat-inactivate EcoRI and HINDIII, the reaction tubes were 
placed in water bath with temperature set at 65°C for 20 minutes. After that, the individual 
PCR products and plasmid were subjected to ligation using the following reaction mixture: 
 
Plasmid pMalC (digested) 1 μl (~ 15ng) 
PCR product (digested) 5 μl (~ 100ng) 
T4 Ligase   1 μl 
10X T4 Ligase buffer  2 μl 
DNA grade water  11 μl 
 
Total reaction volume  20 μl 
 
The reaction mixture was then kept overnight at 16°C. Following which these were added to 
E.coli TOP10 (Genotype: F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Δ lacX74 recA1 
araD139 Δ( araleu)7697 galU galK rpsL (StrR) endA1 nupG) competent cells and plated on 
Ampicillin-containing LB agar plates (explained in detail further). 
 
Preparation of TOP10 E.coli competent cells 
TOP10 E.coli competent cells (Genotype: F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
Δ lacX74 recA1 araD139 Δ( araleu)7697galU galK rpsL (StrR) endA1 nupG) were inoculated 
overnight in 5 ml of LB at 37°C in shaking incubator. Next day, 250 μl from overnight 
inoculum were added to a new inoculation tube containing 25 ml of LB. This is then kept in 
37°C shaking incubator till optical density (OD600) reached 0.35 (0.3 to 0.4). Then, this 
mixture was centrifuged at 3000 RPM for 10 minutes. The supernatant was discarded (all 
procedures done under the hood). Pellet was re-suspended in 12.5ml of 0.1 M calcium 
chloride and placed on ice for at least 1 hour. Following this, another round of 
centrifugation at 300 RPM was carried out. This time the pellet was re-suspended in 2 ml of 
0.1 M calcium chloride. The cells are thus, competent to take up external DNA (plasmid). 
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Transformation using ligated products 
20 μl of ligation reaction mixture was added to 200 μl of above competent cells. This 
mixture was then kept over ice for at least 1 hour with intermittent inversions of tubes. 
Then, 2 minutes of heat shock was provided (transferring to water-bath with temperature 
set at 42°C. This is then transferred back onto ice for 10 minutes. Following this, 750 μl of LB 
was added and the tubes were place in 37°C incubator for 45 minutes. Then, 100 μl of this 
mixture was plated on to LB agar plates containing 100 μg/ml ampicillin and kept overnight 
in 37°C incubator. This is because the plasmid pMalC is resistant to ampicillin. And thus any 
colony growth would signify presence of pMalC plasmid. 
 
Isolation of pure plasmid from transformed colonies 
Individual colonies grown on the plate (as above) were inoculated overnight in 5 ml of LB 
containing 100 μg/ml of ampicillin. Next day, the inoculation tubes were centrifuged at 
10000 RPM for 10 minutes. Pure plasmid was isolated using QIAGEN® Miniprep Plasmid 
Extraction kit. DNA was isolated and eluted as per manufacturer’s instructions and run on 
0.7% DNA agarose gel. The procedure for DNA isolation is as follows: 
After harvesting the cells by centrifugation, supernatant is decanted and the bacterial pellet 
is suspended in 0.3 ml of Buffer P1 (resuspension buffer containing RNAase A). The bacterial 
cell pellet must be resuspended completely by using vortex or by pipetting until no cell 
clumps remain. 0.3 ml of Buffer P2 (contains Sodium hydroxide) is added and mixed by 
inverting tube 4-5 times (care must be taken not to vortex or this will lead to shearing of 
genomic DNA). Incubate at room temperature for 5 mins. 0.3 ml of ice cold Buffer P3 
(contains acetic acid) is then added. This leads to precipitation and the precipitate contains 
genomic DNA, proteins and cell debris and Potassium dodecyl sulphate. The tube is then 
centrifuged at maximum speed for 10 mins. Supernatant should appear to be clear. Qiagen 
Tip® is placed on a rack and equilibrated with 1 ml Buffer QBT and allowed to flow by 
gravity. Supernatant from above step is then added to the column. Tip is then washed using 
2 ml washing buffer (Buffer QC). DNA is then eluted by adding Buffer QF (high salt buffer). 
DNA is precipitated by adding 0.56 ml isopropanol. Reaction is mixed and centrifuged 
immediately at 10000 RPM for 10 mins. DNA pellet is washed with 1 ml of 70% ethanol and 
centrifuged at 10000 RPM for 10 mins. Pellet is air-dryed for 5-10 mins and redissolved in 
suitable amount of DNAase-free water.   
The concentrations of plasmid isolated were calculated using UV spectroscope/NanoDrop®. 
The appropriate amount of plasmid was then sent to Beckman Coulter Genomics® for 
Sanger® sequencing to check for presence of appropriate base pairs in the cloned plasmid. 
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Expression and purification of mouse ghA, ghB and ghC 
Preparation of BL21(DE3) E.coli competent cells 
Similar steps as before. This time BL21 (DE3) E.coli was used. Genotype: F- ompT hsdSB(rB
-mB
-
) gal dcm (DE3). Preparation of competent cells is same as described earlier. 
Transformation of competent cells using isolated plasmid 
1 μl of isolated plasmid was added to 200 μl of BL 21 (DE3)  E.coli competent cells. Rest of 
the procedure similar as described earlier. This time however, the plating was done on LB 
agar plates containing 100 μg/ml ampicillin. 
Large scale protein expression and purification 
Single colonies grown on the LB agar plates containing ampicillin were added to inoculation 
tubes containing 5 ml LB plus 100 μg/ml ampicillin. These were then kept in 37°C shaker 
incubator overnight. Next day, the entire contents were added to 1 litre of LB media 
containing 100 μg/ml ampicillin. The bacterial cells were grown to A600 = 0.6 at 37°C. Then, 
they were induced with 0.4 mM isopropyl β-D-thiogalactoside (IPTG) for 3 hours. Before 
adding IPTG, 1ml of sample is taken aside as un-induced sample. After 3 hours inside the 
37°C shaking incubator, the cells were centrifuged at 3000 RPM for 15 minutes at 4°C.  
The cell pellet was then suspended in 50 ml of lysis buffer (20 mM Tris-HCl, pH 8.0, 0.5 M 
NaCl,  0.2% v/v Tween 20, 1mM EGTA, 1mM EDTA and 5% v/v glycerol) containing 100 
μg/ml lysozyme and 0.1 mM PMSF and incubated over ice for 1 hour. The cell lysate was 
then sonicated at 60 Hz for 30 seconds with an interval of 1 minute (15 cycles were done). 
Then this was centrifuged at 13000 X g for 15 minutes. The supernatant was collected and 
diluted (5-fold) using buffer I (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.2% v/v Tween 20, 1 
mM EDTA, and 5% v/v glycerol) and passed through an amylose resin column (New England 
Biolabs, Beverley, MA).  
Amylose Resin Column is an affinity matrix used in the isolation of proteins fused to MBP. It 
is used in a gravity flow column. The amylose resin is supplied in 20% ethanol and stored at 
4°C. After use, the resin is stored in appropriate buffer with the addition of 0.02% Sodium 
Azide and can be regenerated for further use if required. 
Earlier, 25 ml of the amylose resin column was set up and washed thoroughly with 5 
volumes of autoclaved water, then with 5 volumes of 0.1% SDS and then again with 5 
volumes of autoclaved water.  
The column was then equilibrated by passing through 5 X bed volumes of buffer I. After 
passing thorough supernatant, the column was first washed with buffer I (3-fold column bed 
volume) and then with buffer II (buffer I without Tween 20; 5-fold column bed volume). 
Each fusion protein was then eluted with buffer II containing 10 mM maltose. To further 
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remove any minor contaminants, the fusion protein was applied to Q-Sepharose ion 
exchange column. The bound fraction was washed with column buffer (20 mM Tris-HCl, pH 
8.0, 100 mM NaCl). The fusion protein was eluted using a gradient of 0.3 M to 0.8 M NaCl. 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
The eluted proteins were subjected to SDS-PAGE analysis. The gel consists of resolving gel 
and stacking gel, prepared in between two glass plates (thick and thin glass plate each). To 
prepare 12% resolving gel: 3.3 ml of water, 4 ml 30% acrylamide mix, 2.5 ml 1.5M Tris (pH 
8.8), 0.1ml 10% SDS, 0.1 ml 10% ammonium persulfate and 0.004 ml of TEMED were used. 
After adding in between the glass plates, a layer of water is added on top so as to prevent 
entry of air and aid in polymerisation of gel. Following this, 5% stacking gel was prepared, 
containing 2.7 ml of water, 0.67 ml 30% acrylamide mix, 0.5 ml 1.0M Tris (pH 6.8), 0.1ml 
10% SDS, 0.4 ml 10% APS and 0.004 ml TEMED. After discarding the layer of water on top of 
resolving gel, the stacking gel mixture is added on top of resolving gel. Soon, a set of combs 
is placed on top as well, so as to form wells to load samples. 
The eluted protein samples are prepared by:  
Adding equal volume of treatment buffer (0.5M Tris-HCl, pH 6.8, 4.4% SDS, 300mM 
mercaptoethanol, 10mg/ml bromophenol blue). A total of 10 μl of this mixture was loaded 
onto the wells. The gel tank was filled with 1X running buffer (Tris base 3.02g, Glycine 14.4g, 
SDS 1g). And the gel was run at 120 volts for about 90 minutes. Following which the gel was 
stained in Coomassie blue stain (10% v/w acetic acid, 0.006% (w/v) Coomassie Blue dye, 
90% water). After staining, the gel was subjected to de-stain (30% methanol, 10% acetic 
acid, 60% water). Then the gel is viewed and analysed. 
    
Binding specificities of mouse MBP-ghA, -ghB, ghC for heat-aggregated mouse IgG 
MBP-ghA, -ghB, -ghC, and MBP (10, 5, 2.5, 1.25, 0.6 μg in 100 μl per well in carbonate buffer 
(pH 9.6) were coated to the microtiter wells overnight at 4°C. The wells were blocked with 
2% BSA in PBS for 2 hours. After washing the wells, 10 μg/ml of heat-aggregated IgG 
(concentration of 10 mg/ml) in PBS with 10 mM calcium chloride were added. After 
incubation for 2 hours, Protein A-HRP (1:5000) was added to each well. After 1 hour, colour 
was developed using Sigma-OPD tablets and read at A405.  
 
Globular heads inhibitory hemolytic assays 
For the CP hemolytic assay (CH50):  
Page 33 of 61 
 
Dextrose gelatin Veronal buffer (DGVB2+)  
0.15 mM CaCl2  
141mM NaCl  
0.5 mM MgCl2  
1.8 mM Sodium Barbitone  
3.1 mM Barbitone  
0.1% w/v gelatin; pH 7.4  
Dulbecco phosphate buffer solution (DPBS)  
0.9 mM CaCl2 
2.7 mM KCl  
0.5 mM MgCl2.2H2O  
138 mM NaCl  
8.1 mM Sodium hypophosphate; pH 7.4  
The above solutions were prepared.  
Sheep blood (5 ml) was washed twice with DGVB2+ (in 10 times the volume). And then 
resuspended and adjusted to a concentration of 109 cells (OD541 of 0.7). The OD is measured 
by blanking with 2.8 ml distilled water and reading lysis of sheep red blood cells (SRBC) 
caused by addition of 200 μl of sheep blood. This is then sensitised with anti-SRBC 
antibodies (Hemolysin® Sigma® S1389) and after 2-3 gentle inversions of the tube. This is 
then kept for 15 minutes in 37 degrees incubator and then 15 minutes over ice (now called 
EA cells). Then the tube is washed twice with DGVB; thrice with DPBS and eventually 
resuspended in 10 ml of DGVB2+. 108 EA cells were used for experiments. Serial dilutions of 
serum (100 μl reaction volume) were made by diluting with DGVB2+ (1:10 to 1:1280). To 
each of these, 100 μl of EA cells added. 100 % lysis tube contained 100 μl distilled water + 
100 μl EA cells. The tubes were incubated at 37 degrees for 1 hour and centrifuged at 7000 
RPM for 10 minutes. 140 μl of supernatant was collected and read at OD415 in ELISA plate 
reader. 
 
Purification of IgG isotypes 
Normal mouse serum was passed through a Protein G-sepharose (HiTrap) column. This 
binds IgG to the column. IgG was then eluted with glycine (ph 2.7) and collected in 
Eppendorf tubes. Then immediately, neutralised by adding Tris-HCl (pH 8.0). In order to 
purify the sub-classes of IgG, the purified IgG was passed through a Protein A-sepharose 
column. The flow-through contains IgG3 which does not bind to Protein A. The rest of the 
sub-classes can be eluted at different pH of glycine according to Nikolayenko et al., (2005) 
(IgG1 at pH 4.0, IgG2 at pH 5.0 and IgG4 at pH 4.5).   
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Binding specificities of MBP- ghA, -ghB, -ghC with IgG isotypes 
1 μg/well of heat-aggregated IgG isotypes (concentration of 10 mg/ml) in PBS in 100 μl per 
well in carbonate buffer (pH 9.6) were coated to the microtiter wells overnight at 4°C. The 
wells were blocked with 2% BSA in PBS for 2 hours. After washing the wells, 10, 5, 2.5, 1.25 
μg of MBP-ghA, -ghB, -ghC, and MBP in PBS with 10 mM calcium chloride were added. After 
incubation for 2 hours, antibody against MBP (1:5000) was added and incubated for 1 hour. 
Then, IgG conjugated to HRP (1:5000) was added to each well. After 1 hour, colour was 
developed using Sigma-OPD tablets and read at A405. 
 
Binding specificities of MBP- ghA, -ghB, -ghC with IgM 
1 μg/well of heat-aggregated IgM (BD Pharmingen™ 557275) (concentration of 10 mg/ml) in 
PBS in 100 μl per well in carbonate buffer (pH 9.6) were coated to the microtiter wells 
overnight at 4°C. The wells were blocked with 2% BSA in PBS for 2 hours. After washing the 
wells, 10, 5, 2.5, 1.25 μg of MBP-ghA, -ghB, -ghC, and MBP in PBS with 10 mM calcium 
chloride were added. After incubation for 2 hours, antibody against MBP (1:5000) was 
added and incubated for 1 hour. Then, IgG conjugated to HRP (1:5000) was added to each 
well. After 1 hour, colour was developed using Sigma-OPD tablets and read at A405. 
 
Binding specificities of globular heads of mouse C1q with mouse PrP peptide 
Recombinant mouse PrP was generated in E. coli as described in Kirby et al., (2003). Varying 
concentrations of mouse PrP peptide (20 μg, 10 μg, 5 μg, 2.5 μg, 1.25 μg, 0.62 μg, 0.31 μg, 
0.15 μg) were coated per well overnight onto microtiter plate wells in carbonate buffer (pH 
9.6) and kept at 4°C. The wells were blocked with 2% BSA in PBS for 2 hours. After washing 
the wells, 5 μg/ml of mghA, mghB, mghC and MBP (as negative control) in PBS with 10 mM 
calcium chloride were added. After incubation for 2 hours, anti-MBP (1:5000) was added to 
each well and kept at 37°C. After 1 hour, anti-IgG conjugated to HRP was added and kept in 
37°C incubator for 1 hour. Then, colour was developed using Sigma-OPD tablets and read at 
A405. 
Binding specificities of globular heads of mouse C1q with mouse PTX3 
Equal concentrations of mouse PTX3 (5 μg) was coated to each microtiter plate well in 
carbonate buffer (pH 9.6) and kept at 4°C. The wells were blocked with 2% BSA in PBS for 2 
hours. After washing the wells,different concentrations (5 μg, 2.5 μg, 1.25 μg, 0.62 μg) of 
mghA, mghB, mghC and MBP (as negative control) in PBS with 10 mM calcium chloride were 
added. After incubation for 2 hours, anti-MBP (1:5000) was added to each well and kept at 
37°C. After 1 hour, anti-IgG conjugated to HRP was added and kept in 37°C incubator for 1 
hour. Then, colour was developed using Sigma-OPD tablets and read at A405.    
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Results 
Polymerase Chain Reaction 
o Globular heads of mouse C1q A, B and C chains 
 
Figure 8: DNA agarose gel (0.7%) showing PCR products of globular heads of mouse C1q A, B, C 
chains. Lane 1: Marker ladder (Thermo Fisher Scientific© SM0633); Lane 2: mghA; Lane 3: mghB; 
Lane 4: mghC; Lane 5: negative (water) control. The genes were calculated to be approximately 400 
bp. 
 
Following RNA extraction and cDNA synthesis from mouse spleen, using appropriate 
primers, full-length mouse C1q A, B and C chains were amplified first. Following this, using 
the appropriate full length C1q chains, globular heads of mouse C1q A, B and C chains were 
amplified (mghA, mghB and mghC respectively). The gene for full-length mouse C1q A, B 
and C chains was calculated to be approximately 669 base pairs (bp), 684 bp and 651 bp 
respectively. Using this, the globular heads of mouse C1q chains namely ghA, ghB and ghC 
chains were generated and the genes were calculated to be approximately 400 bp. 
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o Full-length mouse C1q A, B and C chains 
 
 
Figure 9: PCR products are visualised on DNA agarose gels (0.7%). PCR products for the mouse 
globular heads of C1q A, B and C chains as well as full length mouse C1q A, B and C chains are shown 
and labelled accordingly. Lane 1: Marker ladder; Lane 2: C1qA chain 669 bp; Lane 3: Marker ladder; 
Lane 4: C1qB chain 684 bp; Lane 5: marker ladder; Lane 6: inferior cloning attempt for C1qA chain 
(not used for ligation); Lane 7: inferior cloning attempt for C1qB chain (not used for ligation); Lane 8: 
C1qC chain 651 bp; Lane 9: negative (water) control; bp: base pairs). 
 
The recombinant full length and globular heads of mouse C1q A, B and C chains were 
subjected to double digestion using the enzymes EcoRI and HINDIII. The ‘dropped-out’ 
segments co-related correctly to the appropriate estimated base pairs sizes. The gene 
cloned into the pMalc vector can be seen at approximately 4500 bp and when subjected to 
double digestion using the above mentioned enzymes, the C1q B and C chains can be seen 
at approximately 650 bp. 
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Double digestion of ligated products 
 
 
Figure 10: Double digestion of ligated products of full length recombinant C1q B and C chains is 
shown. The ligated products were digested using enzymes EcoRI and HINDIII. Lane 1: Marker ladder; 
Lane 2-5: Full length C1qB chain ‘dropping’ out from the vector pMalC; Lane 6-9: Full length C1qC 
chain ‘dropping’ out from the vector pMalC.  
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The ghA, ghB and ghC modules of mouse C1q can be expressed as soluble fusion proteins 
The globular head regions of mouse C1q A, B, and C chains were expressed as proteins fused 
to MBP in E. coli BL21(DE3) cells. After induction with 0.4 mM isopropyl β-D-thiogalactoside 
for 3 hours, each fusion protein was expressed with a protein band of about 60 kDa (SDS-
PAGE, reducing conditions). Most of the fusion protein bound to affinity column and eluted 
as pure soluble fractions. For further purification, Q-Sepharose anion-exchange column was 
used: Column was washed with autoclaved water X 5 bed volumes. Then washed with 1M 
NaCl to remove off any contaminants. The fusion proteins were passed through the column. 
The flow-through was collected in case no binding occurs. Different gradients of NaCl 
molarity were used (ranging from 0.1 M to 1 M) and the fusion proteins bound at 0.1 M 
NaCl while peak fractions were eluted at 0.3-0.4 M NaCl. 
 
 
 
Figure 11: SDS-PAGE (12% w/v, under reducing conditions) analysis of fusion proteins MBP-ghB. 
Lanes 1 and 7, standard protein molecular mass markers; lane 2, uninduced MBP-ghB; lane 3, 
induced MBP-ghB; lane 4, after sonication MBP-ghB sample; lane 5, purified MBP-ghB; lane 6, after 
ion-exchange MBP-ghB. 
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Figure 12: SDS-PAGE (12% w/v, under reducing conditions) analysis of fusion proteins MBP-ghA and 
MBP-ghC. Lanes 1 and 6, standard protein molecular mass markers; lane 2, uninduced MBP-ghA; 
lane 3, induced MBP-ghA; lane 4, purified MBP-ghA; lane 5, blank; lane 7, uninduced MBP-ghC; lane 
8, induced MBP-ghC; lane 9, purified MBP-ghC.  
The eluted proteins were run on SDS-PAGE (12% w/v, under reducing conditions) and 
analysed for presence of proteins as well as purity of proteins. 
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Factor Xa cleaved MBP-ghA, -ghB, -ghC 
 
Figure 13:   Factor Xa cleavage of MBP-mghA; -mghB; -mghC. The ‘dropped’ out fragment represents 
the mouse globular head of C1q after being cleaved off from MBP. Lane 1: standard protein 
molecular mass marker; Lane 2: blank; Lane 3: MBP-mghA; Lane 4: MBP-mghA subjected to FXa 
treatment; Lane 5: MBP-mghB; Lane 6: MBP-mghB subjected to FXa treatment; Lane 7: MBP-mghC; 
Lane 8: MBP-mghC subjected to FXa treatment. 
The purified proteins were subjected to factor Xa (protease) treatment and observed for 
cleavage of MBP from the globular heads of C1q A, B and C chains (mghA, mghB and mghC 
respectively). 
100 μg of respective protein fused to MBP (MBP-ghA,-ghB,-ghC) was added to Eppendorf 
tube. 1 μl of 1mg/ml concentration Factor Xa protease was added to each tube. Then, 
placed overnight at room temperature. Next day, the samples were run on SDS-PAGE (12% 
w/v, under reducing conditions) and analysed for presence separation of MBP from the 
globular heads. The separation of MBP from globular heads was confirmed in most samples 
although the amount and quality of cleavage varied due to probable presence of 
contaminants and/or concentration of Factor Xa and MBP fusion proteins. 
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IgG isotypes 
 
Figure 14: SDS-PAGE (10% w/v, under reducing conditions) analysis of purified IgG and IgG isotypes. 
Lane 1: IgG4; Lane 2: blank; Lane 3: IgG3; Lane 4: IgG2; Lane 5: IgG1; Lane 6: IgG; Lane 7: standard 
molecular mass protein marker.   
The purified mouse IgG and its isotypes are shown on the gel. The samples were stored in -
20°C upon purification. These samples were then heat-aggregated: 
Samples were placed in water bath with temperature set at 65°C for 20 minutes. Then, 
removed and used for experiments. If not used immediately, then the samples were stored 
in -20°C for future use.  
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Binding specificities of mouse MBP-ghA, -ghB, ghC for heat-aggregated mouse IgG 
 
 
 
Figure 15: Recombinant globular heads of mouse C1q fused to MBP (ghA-MBP, ghB-MBP, ghC-MBP) 
binding to heat- aggregated mouse IgG. Concentration of mouse globular heads (mghA, mghB, 
mghC) and MBP (negative control) are plotted on horizontal axis; Optical density at 405 nanometres 
is plotted along the vertical axis.  
Different concentrations of mouse globular heads of C1q were coated onto wells and 
allowed to bind to heat-aggregated mouse IgG and then probed with HRP conjugated to 
Protein A. MBP-ghA, -ghB, -ghC bound to heat-aggregated IgG in a dose-dependent manner. 
MBP-ghA and MBP-ghB bound higher than MBP-ghC and MBP alone. It is worthwhile to 
note that the native C1q has 18 globular heads (which are clustered) and the recombinant 
ghA, ghB, and ghC are single polypeptide chains, it is difficult to compare such interactions 
with respect to multiple heads of C1q vs single heads of recombinant modules. 
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Binding specificities of mouse MBP-ghA, -ghB, ghC for heat-aggregated mouse IgM 
 
 
Figure 16: Recombinant globular heads of mouse C1q fused to MBP (ghA-MBP, ghB-MBP, ghC-MBP) 
binding to heat- aggregated mouse IgM. Concentration of mouse globular heads (mghA, mghB, 
mghC) and MBP (negative control) are plotted on horizontal axis; Optical density at 405 nanometres 
is plotted along the vertical axis. 
 
Different concentrations of mouse globular heads of C1q were coated onto wells and 
allowed to bind to heat-aggregated mouse IgM. MBP-ghA, -ghB, -ghC bound to heat-
aggregated IgM in a dose-dependent manner. MBP-ghA and MBP-ghC bound higher than 
MBP-ghB and MBP alone. Again it is worth mentioning that the native C1q has 18 globular 
heads (which are clustered) and the recombinant ghA, ghB, and ghC are single polypeptide 
chains, it is difficult to compare such interactions with respect to multiple heads of C1q vs 
single heads of recombinant modules. These results indicate that the interaction of C1q with 
IgM might require multivalent involvement of ghA, -B and –C chains. 
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Globular heads inhibitory haemolytic assays 
 
 
 
Figure 17: Globular heads inhibitory haemolytic assay. Concentration of mouse globular heads 
(mghA, mghB, mghC) and MBP (negative control) are plotted on horizontal axis; Percentage 
haemolysis observed after calculation is plotted along the vertical axis. 
 
To examine the inhibitory effects of MBP-ghA, -ghB, and -ghC on C1q-dependent hemolysis, 
SRBC (E) were sensitized with hemolysin to yield EA cells. MBP-ghA, -ghB, -ghC possess the 
ability to inhibit C1q-dependent hemolysis of sheep erythrocytes coated with hemolysin 
(anti-sheep erythrocyte antibody). To achieve >50% inhibition, nearly 10 ug of MBP-ghA and 
10 ug of MBP-ghB were required whereas MBP-ghC did not achieve 50% inhibition. The 
potencies of the three recombinant proteins as inhibitors of C1q-mediated hemolysis of 
sheep erythrocytes are in the order ghA nearly equal to ghB > ghC.  MBP did not interfere 
significantly with C1q-mediated hemolysis. 
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Binding specificities of native human C1q and mouse MBP- ghA, -ghB, -ghC with IgG 
isotypes 
 
 
Figure 18: Binding of native human C1q with native mouse IgG1. Concentration of native human C1q 
per well is plotted along the horizontal axis; Optical density at 405 nanometres is plotted along the 
vertical axis. 
Equal concentration of mouse IgG1 (10 μg/well) were coated onto wells and different 
concentrations of native human C1q was added. There was a dose-dependent binding 
between human C1q and the purified IgG1.   
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Figure 19: Binding of native human C1q with native mouse IgG3. Concentration of native human C1q 
per well is plotted along the horizontal axis; Optical density at 405 nanometres is plotted along the 
vertical axis. 
 
Equal concentration of mouse IgG3 (10 μg/well) were coated onto wells and different 
concentrations of native human C1q was added. There was a dose-dependent binding 
between human C1q and the purified IgG3.   
 
Binding specificities of mouse IgG1 with mouse MBP- ghA, -ghB, -ghC 
 
 
Figure 20: Binding of globular heads of mouse C1q with native mouse IgG1. Concentrations of mouse 
globular heads (mghA, mghB, mghC) are plotted on horizontal axis; Optical density at 405 
nanometres is plotted along the vertical axis. 
 
Equal concentration of mouse IgG1 (10 μg/well) were coated onto wells and different 
concentrations of globular heads of mouse C1q were added. mghA, mghB and mghC bound 
to IgG1 in a dose-dependent manner. MBP-ghB showed highest binding at 20 μg 
concentration as compared to mghA, mghC.   
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Binding specificities of mouse globular heads of mouse C1q with mouse prion protein peptide 
 
Figure 21: Binding of globular heads of mouse C1q with recombinant mouse PrP peptide. Equal 
concentration (5 μg) of mouse globular heads (mghA, mghB, mghC) and MBP (negative control) are 
plotted on horizontal axis; Optical density at 405 nanometres is plotted along the vertical axis. 
 
Reducing concentrations of mouse PrP peptide was coated on to wells and equal 
concentration (5 μg) of ghA, ghB, ghC and MBP as negative control was added. Highest 
binding strength was observed for ghA at 10 μg concentration and a relative dose 
dependency was observed. MBP as negative control did not appear to interfere significantly 
with the binding process.   
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Binding specificities of globular heads of mouse C1q with mouse PTX3 
 
 
Figure 22: Binding of recombinant globular heads of C1q with PTX3. The recombinant globular heads 
of mouse C1q fused to MBP (ghA-MBP, ghB-MBP, ghC-MBP) binding to heat- aggregated mouse IgG. 
Concentration of mouse globular heads (mghA, mghB, mghC) and MBP (negative control) are plotted 
on horizontal axis; Optical density at 405 nanometres is plotted along the vertical axis. 
 
Equal concentration of mouse PTX3 (10 μg) was coated on to wells and reducing 
concentrations of ghA, ghB, ghC and MBP were added (5 μg, 2.5 μg, 1.25 μg, 0.625 μg). ghB 
and ghC modules were seen to bind well with PTX3 as compared to ghA. Dose dependency 
was observed. MBP as negative control did not significantly interfere with binding process. 
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Discussion 
C1q is known to interact with a range of know ligands via its gC1q domain. The expression 
and functional characterisation of individual mouse gC1q domains has allowed to observe 
for specificity and selectivity of individual globular heads of muse C1q to known ligands. 
Binding specificities of gC1q to IgG as well as IgG isotypes has been studied. It is also seen 
that ghB is inhibitory in the haemolytic assays. 
The generation of recombinant forms of ghA, ghB, ghC will help in better understanding of 
their binding abilities either autonomously or collectively. Also, such studies have not been 
conducted in mouse C1q. This will enable better understanding of mouse system of 
functioning and also help in understanding pathogenesis of diseases in mouse models of 
disease. Future work will involve binding studies involving mouse prion protein. It will be 
interesting to see which globular head binds preferentially to prion protein and also to study 
pathogenesis mechanisms of prion disease. Production of recombinant full-length C1q will 
be the next step. Also structural alignment of mouse gC1q in relation to human gC1q will be 
conducted. 
MBP-ghA, -ghB, -ghC bound to heat-aggregated IgG in a dose-dependent manner. MBP-ghA 
and MBP-ghB bound higher than MBP-ghC and MBP alone. Studies have shown that the 
individual modules of gC1q bind to their ligands differentially. Heat-aggregated IgG binds 
preferentially to ghB and ghA while heat-aggregated IgM shows preferential binding to ghC 
(Kishore et al., 2003). C1q is known to bind via its gC1q domain to non-aggregated IgG at the 
Fc region weakly (Duncan and Winter, 1988; Hughes-Jones and Gardner, 1979), but the 
strength of binding increases nearly a thousand-fold when immune complexes (or heat-
aggregation) of IgG are involved (Kishore et al., 2002) The binding site has been localised to 
CH2 domain of the Fc portion of IgG with the residues Glu (E)-318, Lys (K)-320 and Lys (K)-
322 being significant in this binding (Duncan and Winter, 1988). Binding site of C1q is 
different in human and mouse IgG sub-types (Idusogie et al., 2001; Idusogie et al., 2000; 
Thommesen et al., 2000) and so are the binding affinities and complement-activating 
functions (Leatherbarrow and Dwek, 1984; Bindon et al., 1988). Interaction of C1q with CRP 
is known to occur via the gC1q region (Agrawal et al., 2001). Activation of acute phase 
protein, CRP leads to beneficial anti-inflammatory host defence system. PTX3 is structurally 
similar to CRP and also binds C1q via the gC1q region (Nauta et al., 2003). 
MBP-ghA, -ghB, -ghC bound to heat-aggregated IgM in a dose-dependent manner. MBP-ghA 
and MBP-ghC bound higher than MBP-ghB and MBP alone. It is known for earlier studies 
that the interaction of C1q with most of the negatively charged ligands includes an initial 
step of binding to residues on gC1q apex, followed by rotation of gC1q facilitated by Ca2+ 
and then binding by the residues on ghB or C1qB chain. The three residues LysA200 from A 
chain, TyrB175 from B chain and LysC170 from C chain, all from apex of gC1q region are crucial 
and take part in the interaction with immunoglobulins (Gadjeva et al., 2008). 
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Both MBP-ghA and MBP-ghB also inhibited C1q-dependent hemolysis of IgG sensitized 
sheep erythrocytes. The specificity and selectivity gives a high potential of flexibility and 
versatility to C1q for interaction with ligands. However it is worth noting that the full intact 
C1q molecule has 6xC1qA, 6xC1qB and 6xC1qC chains and the studies conducted here 
involve on individual ghA,-B, and –C region (Kishore et al., 2003). 
Binding of prion peptide with gC1q region would help in understanding the pathogenesis of 
prion disease. Currently, it is understood that PrPSc in the gut activates the complement 
system mainly by C1q and leads to it being opsonised and undergoes uptake by dendritic 
cells. The dendritic cells lead to its transportation into the lymphatic system wherein the 
follicular dendritic cells facilitate replication and further involvement of CNS. PrP has been 
found to be capable of activating complement in an antibody-independent manner (Mitchell 
et al., 2007). Earlier studies have shown the importance of Ca2+ in the binding between C1q 
and PrP with Ca2+ leading to a conformational change in the globular region of prion protein 
leading to C1q binding (Blanquet-Grossard et al., 2005).  
The study of recombinant gC1q region heads will help in understanding the effects of PTX3 
activation on the complement system. It is known that binding of C1q via gC1q region to 
PTX3 is highly electrostatic in nature as the interaction in vitro is highly dependent on the 
ionic strength of binding buffers. The binding is also known to be pH-dependent thereby 
implying the importance of inflammatory site pH in the body. And as mentioned previously, 
the residues (TyrB175 and LysC170) from the apex and side surface of ghB are vital in the 
interaction with PTX3 (Roumenina et al, 2006). 
C1q is involved in development of SLE. Immune complexes trigger the complement pathway 
and C1q is thought to play a crucial role in tissue injury. However, congenital complete or 
partial deficiency of C1q also leads to SLE. And C1q is also involved in apoptotic cell 
clearance as well as immunoregulation of B cells and T cells providing indication of 
beneficial role in SLE (Sontheimer et al., 2005).  
The anti-C1q antibodies generated in human body are also directed against the gC1q region 
namely against gh-A, -B and –C regions. The anti-C1q autoantibodies against ghB have been 
shown to inhibit binding of C1q to IgG and CRP leading to inefficient apoptotic cell and 
immune complex clearance as well as leading to generation of pro-inflammatory cytokines 
(Radanova et al., 2012; Tsacheva et al., 2007). Production of mouse gC1q domains will be 
helpful in antibody mapping of anti-C1q autoantibodies recognising gC1q region. 
The production of individual gC1q domains also open up the possibilities for mutational 
analysis studies, helping in assessment of residues and motifs involved in C1q interaction 
with its ligands. 
C1q-deficient mice (C1qa-/-) are highly susceptible to development of SLE caused by 
impairment in clearance of apoptotic cells. These C1q knock-out mice develop antinuclear 
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antibodies and glomerulonephritis (associated with multiple apoptotic bodies). C1q has also 
been found to be involved in apoptotic cell clearance without the need for C3 activation 
(Botto et al., 1998; Mitchell et al., 1999). Antibodies can be raised against the individual 
globular heads of mouse gC1q region and can be integrated with C1q knock-out mouse 
model of disease for study of involvement of individual globular heads or antibodies against 
individual gC1q heads in disease pathogenesis. Future work involving production of full-
length recombinant mouse C1q can again be tested in C1q-deficient mice to test for 
efficiency and probable role in disease therapeutics as well as characterisation of in vivo 
functioning of recombinant mouse C1q.     
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Appendix 1: Alignment of mouse gC1q with human gC1q 
 
 
Alignment of the mouse gC1q domains with the human gC1q domains, Collagen X and ARCP 
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Appendix 2: Details of protein sequence of mouse gC1q 
Complete mouse protein sequences ( with signal peptide in bold 
underline. C1Q domains in BOLD 
>mouse_c1qa NP_031598.2 
METSQGWLVACVLTMTLVWTVAEDVCRAPNGKDGAPGNPGRPGRPGLKGERGEPGAAGIRTG
IRGFKGDPGESGPPGKPGNVGLPGPSGPLGDSGPQGLKGVKGNPGNIRDQPRPAFSAIRQNP
MTLGNVVIFDKVLTNQESPYQNHTGRFICAVPGFYYFNFQVISKWDLCLFIKSSSGGQPRDS
LSFSNTNNKGLFQVLAGGTVLQLRRGDEVWIEKDPAKGRIYQGTEADSIFSGFLIFPSA 
>mouse_c1qb NP_033907.1 
MKTQWGEVWTHLLLLLLGFLHVSWAQSSCTGPPGIPGIPGVPGVPGSDGQPGTPGIKGEKGL
PGLAGDLGEFGEKGDPGIPGTPGKVGPKGPVGPKGTPGPSGPRGPKGDSGDYGATQKVAFSA
LRTINSPLRPNQVIRFEKVITNANENYEPRNGKFTCKVPGLYYFTYHASSRGNLCVNLVRGR
DRDSMQKVVTFCDYAQNTFQVTTGGVVLKLEQEEVVHLQATDKNSLLGIEGANSIFTGFLLF
PDMDA 
>mouse_c1qc NP_031600.2 
MVVGPSCQPPCGLCLLLLFLLALPLRSQASAGCYGIPGMPGMPGAPGKDGHDGLQGPKGEPG
IPAVPGTRGPKGQKGEPGMPGHRGKNGPRGTSGLPGDPGPRGPPGEPGVEGRYKQKHQSVFT
VTRQTTQYPEANALVRFNSVVTNPQGHYNPSTGKFTCEVPGLYYFVYYTSHTANLCVHLNLN
LARVASFCDHMFNSKQVSSGGVLLRLQRGDEVWLSVNDYNGMVGIEGSNSVFSGFLLFPD 
 
 
mouse sequences without sequence peptide (all residue 
numberings are according to these sequences) C1q domain in 
BOLD. 4 residues in front of each and 3 residues at the back 
are underlined. These were taken in addition to the domain for 
modeling the domain structure ( to align properly to Gerard's 
structural alignment. 
>mouse_c1qa NP_031598.2 
METSQGWLVACVLTMTLVWTVAEDVCRAPNGKDGAPGNPGRPGRPGLKGERGEPGAAGIRTG
IRGFKGDPGESGPPGKPGNVGLPGPSGPLGDSGPQGLKGVKGNPGNIRDQPRPAFSAIRQNP
MTLGNVVIFDKVLTNQESPYQNHTGRFICAVPGFYYFNFQVISKWDLCLFIKSSSGGQPRDS
LSFSNTNNKGLFQVLAGGTVLQLRRGDEVWIEKDPAKGRIYQGTEADSIFSGFLIFPSA 
>mouse_c1qb NP_033907.1 
MKTQWGEVWTHLLLLLLGFLHVSWAQSSCTGPPGIPGIPGVPGVPGSDGQPGTPGIKGEKGL
PGLAGDLGEFGEKGDPGIPGTPGKVGPKGPVGPKGTPGPSGPRGPKGDSGDYGATQKVAFSA
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LRTINSPLRPNQVIRFEKVITNANENYEPRNGKFTCKVPGLYYFTYHASSRGNLCVNLVRGR
DRDSMQKVVTFCDYAQNTFQVTTGGVVLKLEQEEVVHLQATDKNSLLGIEGANSIFTGFLLF
PDMDA 
>mouse_c1qc NP_031600.2 
MVVGPSCQPPCGLCLLLLFLLALPLRSQASAGCYGIPGMPGMPGAPGKDGHDGLQGPKGEPG
IPAVPGTRGPKGQKGEPGMPGHRGKNGPRGTSGLPGDPGPRGPPGEPGVEGRYKQKHQSVFT
VTRQTTQYPEANALVRFNSVVTNPQGHYNPSTGKFTCEVPGLYYFVYYTSHTANLCVHLNLN
LARVASFCDHMFNSKQVSSGGVLLRLQRGDEVWLSVNDYNGMVGIEGSNSVFSGFLLFPD 
 
# here are the mouse domains extracted from the mouse c1q 
proteins, 
>mc1qa QPRP-4 extra residues taken in front and 3 from back 
FPS 
QPRPAFSAIRQNPMTLGNVVIFDKVLTNQESPYQNHTGRFICAVPGFYYFNFQVISKWDLCL
FIKSSSGGQPRDSLSFSNTNNKGLFQVLAGGTVLQLRRGDEVWIEKDPAKGRIYQGTEADSI
FSGFLIFPS 
>mc1qb TQKV-4 extra residues taken in front and 3 from back 
FPD 
TQKVAFSALRTINSPLRPNQVIRFEKVITNANENYEPRNGKFTCKVPGLYYFTYHASSRGNL
CVNLVRGRDRDSMQKVVTFCDYAQNTFQVTTGGVVLKLEQEEVVHLQATDKNSLLGIEGANS
IFTGFLLFPD 
>mc1qc KHQS-4 extra residues taken in front and 3 from back 
FPD 
KHQSVFTVTRQTTQYPEANALVRFNSVVTNPQGHYNPSTGKFTCEVPGLYYFVYYTSHTANL
CVHLNLNLARVASFCDHMFNSKQVSSGGVLLRLQRGDEVWLSVNDYNGMVGIEGSNSVFSGF
LLFPD 
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Appendix 3: Most variable residues in mouse gC1q 
Table 3 
Most variable residues within mouse gC1q identified by ConSurf 
   m-ghA   m-ghB   m-ghC  
1  ISO
1
 98 • THR
2
 102 • THR
1
 101 
2 • MET
1
 103 • ASN
1
 104 • GLN
1
 102 
3 • THR
1
 104 • SER
1
 105 • TYR
1
 103 
4 • LEU
1
 105 • PRO
1
 106 • GLU
2
 105 
5 • GLY
1
 106 • ARG
1 108 • ALA
1
 106 
6  LYS
2
 113 • PRO
1
 109 • ALA
1
 108 
7 ◦ SER
1
 120 • GLN
1
 111 • ARG
1
 111 
8 ◦ PRO
1
 121  LYS
1
 117 • SER
1
 114 
9 • HIS
1
 125 ◦ ALA
2
 122 ◦ PRO
1
 119 
10 • ARG
1
 128 ◦ GLU
1
 124 ◦ GLY
1
 121 
11  ALA
1
 132  ARG
1 129 • PRO
1
 125 
12  LYS
2
 146  LYS
1
 136 • SER
1
 126 
13  PHE
1
 152  LEU
1
 140  GLU
1
 133 
14 ◦ SER
2
 157 • ASN
1
 156  LEU
1
 137 
15 ◦ GLY
1
 158 • VAL
1
 158 ◦ ASN
1
 155 
16 ◦ GLY
1
 159 • ARG
1
 159 ◦ LEU
1
 158 
17 ◦ PRO
1
 161 • GLY
2
 160 ◦ ALA
1
 159 
18 ◦ ARG
2
 162 • ARG
1
 161 ◦ ARG
1
 160 
19 ◦ ASP
1
 163 • ASP
1
 162 • PHE
1
 169 
20  THR
1
 170 • ARG
1
 163 • ASN
1
 170 
21  LEU
1
 175 • MET
1
 166 ◦ ARG
1
 182 
22 • GLN
1
 186 • GLN
1
 167 ◦ GLN
1
 184 
23 • ARG
1
 188 • LYS
1
 168 ◦ ARG
1
 185 
24 • ARG
1
 189 ◦ GLN
1
 177 • ASP
1
 195 
25 ◦ PRO
1
 199 ◦ ASN
2
 178 • TYR
1
 196 
26 ◦ ALA
1
 200 ◦ THR
2
 179  GLU
1
 203 
27  THR
1
 208 ◦ PHE
2
 180    
28    • LYS
2
 190    
29    • GLU
1
 192    
30    • GLN
1
 193    
31    ◦ ISO
2
 210    
32    ◦ GLU
1
 211    
Residues are sorted based on their position. (•) and (◦) indicate possible important residue clusters for ligand 
binding. Clusters are defined wherever residues are at/within 3-residue distance from each other. 
Hydrophobic and ring residues are underlined. Arginine and Lysine residues are shown in boldface. Numbers in 
superscript indicate the “rank” of the residue given by ConSurf (1-9, most variable to most conserved). Only 
the most variable residues (ranks 1 and 2) are shown here. 
 
